Wall Street Journal28 天
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK GSK0.31%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...
CNN28 天
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...
Wall Street Journal28 天
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK GSK1.94%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...
Reuters28 天
GSK shares jump on $2.2 billion Zantac settlement
Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Oct 10 (Reuters) - GSK (GSK.L ...
The Financial Times28 天
GSK’s problem is it has more than one source of pain
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Zantac may have been a heartburn medicine but it caused one almighty headache for GSK chief executive Emma ...
Reuters28 天
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...
GSK settles vast majority of Zantac claims for $2.2 billion
GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac ...
Seeking Alpha28 天
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 ...
FierceBiotech8 天
GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased ...
GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...
Yahoo Finance28 天
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
(Bloomberg) -- GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was ...
Yahoo Finance24 天
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction ...
On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...